Psychiatric Annals
September 1, 2022
Mitch Earleywine, Zachary Herrmann
5 citations
Initial promise and dire need have inspired the multiple research programs of the second psychedelic renaissance. Serotonergic psychedelics (psilocybin, lysergic acid diethylamide, and ayahuasca) have decreased end-of-life anxiety in cancer patients, treatment-resistant depression, alcohol dependence, social anxiety in autistic adults, and nicotine dependence when applied with supportive...
August 22, 2022
John M. Pederson, Kathryn Cowie, Averi Barrett et al.
BACKGROUND Psilocybin is a naturally occurring psychedelic that induces feelings of euphoria and spiritual awakening when administered in doses of approximately 20-30 mg/70 kg. In the last decade, there has been renewed interest in using psilocybin for major depressive disorder (MDD). OBJECTIVE This individual patient data meta-analysis will investigate the efficacy and safety of psilocybin for...
Archives of Clinical Neuropsychology
August 17, 2022
Brian Peacock
3 citations
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depression, anxiety, posttraumatic stress disorder, and substance use disorders. As ketamine therapy is already available in general medicine and 3,4 Methylenedioxymethamphetamine (MDMA) and psilocybin are in late-stage clinical trials, neuropsychologists...
Zeitschrift für Phytotherapie
August 1, 2022
Carhart-Harris R, Giribaldi B, Nutt DJ et al. Trial of psilocybin versus escitalopram for depression. N Engl J Med 2021; 384: 1402–1411. doi:10.1056/ NEJMoa2032994
Journal of Palliative Medicine
August 1, 2022
William E Rosa, Zachary Sager, Megan Miller et al.
49 citations
Psychedelic-assisted therapy (PAT) is a burgeoning treatment with growing interest across a variety of settings and disciplines. Empirical evidence supports PAT as a novel therapeutic approach that provides safe and effective treatment for people suffering from a variety of diagnoses, including treatment-resistant depression, substance use disorder, and post-traumatic stress disorder. Within...
Frontiers in Psychiatry
July 7, 2022
Maggie Kiraga, Kim P. C. Kuypers, Malin V. Uthaug et al.
24 citations
Anxiety disorders are the most common type of psychiatric disorders among Western countries. Evidence-based treatment modalities including pharmacological and cognitive-behavioral therapy result in deficient treatment responses. Historical and recent research suggests psychedelic drugs may be efficacious in alleviating anxiety-related symptoms among healthy and clinical populations. The main...
Frontiers in Pharmacology
June 28, 2022
Nataliya S. Vorobyeva, Alena A. Kozlova
16 citations
Classical psychedelics represent a family of psychoactive substances with structural similarities to serotonin and affinity for serotonin receptors. A growing number of studies have found that psychedelics can be effective in treating various psychiatric conditions, including post-traumatic stress disorder, major depressive disorder, anxiety, and substance use disorders. Mental health disorders...
Journal of Psychedelic Studies
June 9, 2022
Annie M. Mccartney, Hugh McGovern, Alexander de Foe
8 citations
Abstract Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state...
Neuroscience & Biobehavioral Reviews
June 6, 2022
Corinna L. Felsch, Kim P. C. Kuypers
23 citations
BACKGROUND: Current first-line treatment for social anxiety disorder (SAD), one of the most prevalent anxiety disorders, is limited in its efficacy. Hence, novel treatment approaches are urgently needed. The current review suggests a combination of meditation-based interventions and the administration of a psychedelic as a future alternative treatment approach. While both separate treatments...
European Psychiatry
June 1, 2022
L. Silva, L. Bravo
Introduction Ayahuasca is an hallucinogenic tea prepared from the Amazonian vine Banisteriopsis caapi and the leaves of the plant Psychotria Viridis. Banisteriopsis caapi contains monoamine oxidase inhibitors (MAO) that render the N, N-dimethyltryptamine (DMT) of Psychotria Viridis active. This brew is being used as a sacrament in syncretic religions in urban areas of Brazil and worldwide with...